Overview

Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)

Status:
Completed
Trial end date:
2005-06-30
Target enrollment:
Participant gender:
Summary
This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge. A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Carvedilol